GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

The positive opinion for Zenrelia, or ilunocitinib, opens the way for the product's marketing authorization in the European Union in the next 60 days. The company said it expects to launch Zenrelia ...

EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...